Vnitr Lek 2009, 55(3):223-226
Thrombotic Complications in Children with Cancer
- Dublin University, Trinity College Dublin and Our Lady's Children's Hospital, Crumlin Dublin 12, Ireland
The last decade has seen advances in treatment of life-threatening disease in children - especially cancer where the overall cure rate is now in the region of 80%. Similar to adults, children with cancer are at a substantial risk of developing thromboembolism (TE). One of the costs of achieving this has been more children developing thrombotic disease, the majority of which are related to indwelling vascular catheters and as a result TE is being diagnosed with increasing frequency in these younger patients. In the Canadian Paediatric Thrombophilia Registry, 20% of the patients with TE had cancer. This figure is in contrast to only 2.3 cases of malignancy/1000 children and an estimated incidence of thrombosis of 0.7/100,000 in the general paediatric population. However, the true prevalence of TE in children with cancer is unknown as rates can vary from 1% to as high as 44% [5] and this reflects the heterogeneity of such studies in terms of; (i) type of cancer, (ii) was the TE, symptomatic or asymptomatic and (iii) were the studies prospective or retrospective. Happening alongside these advances have been an explosion in our knowledge of the understanding at the molecular level of blood coagulation in particular how the natural anticoagulant and fibrinolytic pathways work and how they differ in children and adults. Stemming from these discoveries new anticoagulant therapeutics have become available to the paediatrian and over the next decade their true place in the treatment of childhood thrombotic disease will be established.
Keywords: thrombotic complication; children; cancer; thromboembolism
Received: February 2, 2009; Published: March 1, 2009 Show citation
References
- Charles A. Owen Jr A. History of Blood Coagulation. In: Nicols WJ, Walter Bowie EJ (eds). Mayo Foundation for Medical Education and Research. Minnesota: Rochester 2001.
- Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-425.
Go to original source...
Go to PubMed...
- Smith OP. Thrombotic Disorders. In: SmithO, Hann I (eds). Essential Paediatric Haematology. Martin Dunitz Publishers 2002: 131-140.
Go to original source...
- Monagle P, Adams M, Mahoney M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47: 763-766.
Go to original source...
Go to PubMed...
- Wiernikowski JT, Athale UH. Thromboembolic complications in children with cancer. Thromb Res 2006; 118: 137-152.
Go to original source...
Go to PubMed...
- Smith OP, Hann I. Clinical features and therapy of lymphoblastic leukaemia. In: Arcesi R, Hann IM, Smith OP (eds). Paediatric Haematology. Blackwell Publishing 2006.
Go to original source...
- Mitchell LG, Andrew M, Hanna K et al. Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events inchildren with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacementin Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-516.
Go to original source...
Go to PubMed...
- Appel IM, Hop WC, van Kessel-Bakvis C et al. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008; 100: 330-337.
Go to original source...
Go to PubMed...
- Nowak-Göttl U, Heinecke A, von Kries R et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103: 165-172.
Go to original source...
Go to PubMed...
- Mauz-Körholz C, Junker R, Göbel U et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 2000; 83: 840-843.
Go to original source...
Go to PubMed...
- Nowak-Göttl U, Ahlke E, Fleischhack G et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101: 2529-2533.
Go to original source...
Go to PubMed...
- Tabori U, Beni-Adani L, Dvir R et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 2004; 43: 633-636.
Go to original source...
Go to PubMed...
- Deitcher SR, Gajjar A, Kun L et al. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 2004; 145: 848-850.
Go to original source...
Go to PubMed...
- Athale U, Cox S, Siciliano S et al. Thromboembolism in children with sarcoma. Pediatr Blood Cancer 2007; 49: 171-176.
Go to original source...
Go to PubMed...
- Ruud E, Holmstrøm H, De Lange C et al. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies - a randomized, controlled study. Acta Paediatr 2006; 95: 1053-1059.
Go to original source...
Go to PubMed...
- Mitchell L, Andrew M, Hanna K et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90: 235-244.
Go to original source...
Go to PubMed...
- Elhasid R, Lanir N, Sharon R et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001; 12: 367-370.
Go to original source...
Go to PubMed...
- Nowak-Göttl U, Münchow N, Klippel U et al. The course of fibrinolytic proteins in children with malignant bone tumours. Eur J Pediatr 1999;158 (Suppl 3): S151-S153.
Go to original source...
Go to PubMed...